ASLAN Pharmaceuticals Limited
ASLAN Pharmaceuticals Limited (ASLN) PE Ratio — Current & Historical Data
Trailing twelve months (TTM) P/E, forward P/E, PEG, and annual PE history — from market prices and filings.
asln · pe ratio · data through Dec 31, 2023
Core PE Ratio Metrics
Trailing 12 months · TTMThe price-to-earnings (P/E) ratio for ASLAN Pharmaceuticals Limited (ASLN) measures how much investors pay for each dollar of the company's trailing earnings. ASLN's current PE ratio of N/A is calculated by dividing its stock price of $0.60 by its TTM earnings per share of -$10.75.
Source: FMP · /ratios-ttm · /analyst-estimates · 2023-12-31
PE Ratio History
2014 – 2023 · Annual▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare (Annual)
PE Ratio vs Peers
Biotechnology · 6 peers · Annual PE| Company | Market Cap | PE (Annual) | vs Avg | EPS (TTM) |
|---|---|---|---|---|
ASLAN Pharmaceuticals LimitedYou ASLN | $777M | N/A | — | -$10.75 |
 Albireo Pharma, Inc. ALBO | $916M | N/A | — | -$7.87 |
 Avid Bioservices, Inc. CDMO | $799M | N/A | — | -$2.23 |
 Chimerix, Inc. CMRX | $801M | N/A | — | -$0.99 |
 Exscientia plc EXAI | $633M | N/A | — | -$1.18 |
 Harpoon Therapeutics, Inc. HARP | $865M | N/A | — | -$20.24 |
 Intercept Pharmaceuticals, Inc. ICPT | $795M | 3.63x | — | $3.41 |
* N/A — Company is not profitable (TTM) · excluded from industry average · ▸ FMP /stock-peers + /ratios?limit=1 · priceToEarningsRatio
Annual PE Ratio History
| Fiscal Year End | PE Ratio | EPS (TTM) | YoY Change | PE vs Max |
|---|---|---|---|---|
2023-12-31Latest FY2023 | — | $-10.75 | — | |
2022-12-31 FY2022 | — | $-14.73 | — | |
2021-12-31 FY2021 | — | $-10.66 | — | |
2020-12-31 FY2020 | — | $-9.32 | — | |
2019-12-31 FY2019 | — | $-28.98 | — | |
2018-12-31 FY2018 | — | $-28.17 | — | |
2017-12-31 FY2017 | — | $-32.72 | — | |
2016-12-31 FY2016 | — | $-6.92 | — | |
2015-12-31 FY2015 | — | $-24.22 | — | |
2014-12-31 FY2014 | — | $-115.25 | — |
▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare · Zero extra API
About PE Ratio & Methodology
The price-to-earnings (P/E) ratio for ASLAN Pharmaceuticals Limited (ASLN) measures how much investors pay for each dollar of the company's trailing earnings. ASLN's current PE ratio of N/A is calculated by dividing its stock price of $0.60 by its TTM earnings per share of -$10.75.
Frequently asked questions
ASLN pe ratio · 6 questionsASLN's current PE ratio is N/A as of 2026-06-09, based on a stock price of $0.60 and TTM EPS of -$10.75. Data sourced from Financial Modeling Prep via ASLN's SEC 10-K and 10-Q filings.
▸ Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · ASLAN Pharmaceuticals Limited SEC 10-K & 10-Q filings · US GAAP · Updated: 2026-06-09